Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.83) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.83), Zacks reports. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.54 million.
Xenetic Biosciences Stock Performance
Shares of Xenetic Biosciences stock traded down $0.14 on Thursday, hitting $3.15. 59,989 shares of the company’s stock were exchanged, compared to its average volume of 7,299. The company has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $3.98. The stock has a market capitalization of $4.85 million, a PE ratio of -1.08 and a beta of 2.29. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.97.
Xenetic Biosciences Company Profile
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- Upcoming IPO Stock Lockup Period, Explained
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Fintech Stocks With Good 2021 Prospects
- Jeff Brown’s Exegesis AI Stock Picks
- What is the NASDAQ Stock Exchange?
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.